Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 213

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease

CAPRILLI, R., ANDREOLI, A., CAPURSO, L., CORRAO, G., ALBASIO, G. D., GIOIENI, A., ASSUERO LANFRANCHI, G., PALADINI, I., PALLONE, F., PONTI, V., RIGO, G. P., ROSSINI, F. P., STURNIOLO, G. C., TONELLI, F., VALPIANI, D., THE GRUPPO ITALIANO PER LO STUDIO DEL COLON E DEL RETTO (GISC)·1994·Alimentary Pharmacology & Therapeutics

Abstract

SUMMARY: Methods:A multicentre randomized controlled trial was conducted to evaluate the efficacy of oral mesalazine (5‐aminosalicylic acid) for the prevention of post‐operative recurrence in 110 patients operated on for Crohn's disease by first intestinal resection. Patients were randomly allocated to receive 2.4 g/day of mesalazine, or no treatment at all. The protocol included colonoscopy with ileoscopy at 6 months and yearly thereafter. Recurrence was denned on the basis of endoscopic criteria and classified as mild or severe. Results: The demographic and pre‐trial characteristics were very similar in the two groups of patients. The cumulative proportion of recurrence at 6, 12 and 24 months was significantly lower in the mesalazine group than in untreated group (P= 0.002). At 24 months the cumulative proportions of endoscopic recurrence were 0.52 + 0.12 (± S.E.M.) and 0.85 (±0.07), respectively. At the same time the cumulative proportions of symptomatic recurrence were 0.18 + 0.09 and 0.41 + 0.09 (P= 0.006). The cumulative proportions of the severe recurrence was also significantly lower in the mesalazine group (0.17±0.09 vs.0.38±0.09;P= 0.021).Conclusions: The preliminary results of this study show that administration of oral mesalazine soon after surgery is effective in preventing post‐operative endoscopic recurrence in Crohn's disease over a 2‐year period. It is estimated that this treatment prevents 39% of all recurrences and 55% of the severe recurrences.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.1994.tb00158.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 213

Metadata

Authors
CAPRILLI, R., ANDREOLI, A., CAPURSO, L., CORRAO, G., ALBASIO, G. D., GIOIENI, A., ASSUERO LANFRANCHI, G., PALADINI, I., PALLONE, F., PONTI, V., RIGO, G. P., ROSSINI, F. P., STURNIOLO, G. C., TONELLI, F., VALPIANI, D., & (GISC), T. G. I. P. L. S. D. C. E. D. R.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
1994-02
Volume
8
Issue
1
Pages
35-43
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1999329203
Cited by
213
References
2
FWCI
7.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. https://app.cochat.ai/papers/10.1111/j.1365-2036.1994.tb00158.x
The paper
CAPRILLI, R., ANDREOLI, A., CAPURSO, L., CORRAO, G., ALBASIO, G. D., GIOIENI, A., ASSUERO LANFRANCHI, G., PALADINI, I., PALLONE, F., PONTI, V., RIGO, G. P., ROSSINI, F. P., STURNIOLO, G. C., TONELLI, F., VALPIANI, D., & (GISC), T. G. I. P. L. S. D. C. E. D. R. (1994). Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.1994.tb00158.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.